The EMBL Imaging Centre has received €7 million in support from Boehringer Ingelheim Stiftung to further advance its cutting-edge imaging technologies.

Biomanufacturing promises domestic, sustainable, sovereign and resilient production. Capacities are trapped in outdated scale-up processes. SPRIND urges investment and disruptive innovation to propel biomanufacturing. Demands are decentralised, non-sterile & continuous biomanufacturing capabilities.

CSE25-Press-images-10

Resilience and quality connections define Chemspec Europe 2025.

A landmark study in the UK shows that mitochondrial replacement therapy can prevent babies from inheriting diseases caused by mutant mitochondria.

That deserves a closer look: The recently announced partnership between Axxam S.p.A., a leading provider of integrated early discovery services, and Molecular Health GmbH, a pioneer in AI-powered data solutions for pharmaceutical R&D, is more than a standard collaboration. It exemplifies the convergence of consolidated in-vitro biology-led drug discovery with modern, data-intelligent drug development methodologies. As an example for breaking the silos of clinical and preclinical target validation.

Spain’s biotech sector drives innovation, economic growth, and scientific ­excellence. With strong R&D investment, global research impact, and a leading role in gender equality, it’s a key player in health, sustainability, and strategic autonomy. BIOSPAIN 2025 in Barcelona will showcase its potential and connect global biotech leaders.

Pichia pastoris (syn. Komagataella phaffii), a methylotrophic yeast, is a proven platform for pharmaceutical protein production. However, its potential reaches far beyond. As a reliable, scalable, and cost-efficient platform for recombinant protein expression, Pichia is equally suited for industrial enzymes, food & feed, diagnostics, and biomaterials.

In today’s rapidly evolving world, adapting to demand volatilities while ­ensuring uninterrupted supply of biological medicines is more critical than ever. At ­Boehringer Ingelheim, our global biopharmaceutical network delivers flexibility, resilience, and ­reliability. By leveraging harmonised procedures, standardised setups, and innovative logistics, we ­ensure the biologics we produce reach those in need – even during unexpected challenges.

In the life sciences industry, Quality Management (QM) has long been ­synonymous with compliance: checking boxes to meet regulatory demands. But that ­definition no longer holds up. Today, QM must do much more than ensure compliance; it needs to ­enable speed, scalability, and sustained innovation across complex, global operations. To do that, prominent gaps need to be filled.

It all began with a view from the window of the 15th floor of Bayer’s site in ­Berlin, reminiscent of Boston before it became one of the most important biotech hotspots in the world. This inspired the vision of developing the Bayer Campus into “Boston an der Spree” – a vibrant healthcare campus that fosters collaboration and innovation.